Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses recent advancements in clinical trials for patients with idiopathic pulmonary fibrosis (IPF) and progressive ...
Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, ...
Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 ...
Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional ...
Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive lung conditions that require early and sustained intervention1,2 CHMP's positive opinion ...
Boehringer Ingelheim’s Jascayd receives European marketing approval to treat adults with IPF & progressive pulmonary fibrosis: Ingelheim, Germany Saturday, July 18, 2026, 15:00 ...
The MarketWatch News Department was not involved in the creation of this content. -- A new pooled analysis of the FIBRONEER(TM)-IPF and FIBRONEER(TM)-ILD trials resulted in a nominally significant ...
Boehringer Ingelheim today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved JASCAYD ® (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results